Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Antares takes cost-cutting measures:

This article was originally published in Clinica

Executive Summary

Antares Pharma has decided to close its manufacturing and assembly facilities in Minneapolis, Minnesota, and outsource these activities. The company, which is developing needle-free injectors and transdermal gel products, says it wants to focus on design and engineering rather than investing its resources in expanding its production capabilities. The company restructured its debt financing earlier this month. Its partner, Ferring Pharmaceuticals, recently launched its Vision reusable device, and Lilly is examining the possibility of using its needle-free technology with several of its pharmaceuticals.

You may also be interested in...



PCPC Working To Ensure State EPR Programs Are ‘Least Onerous As Possible’

The Personal Care Products Council is engaging on state legislation for extended producer responsibility programs, which impose the cost of recycling plastic materials on manufacturers. Emerging bills to prohibit use of the ‘chasing arrows’ recycling symbol on consumer packaging also have the trade group’s attention.

In-Person US FDA Meetings Returning? Agency Will Support Those Events At HQ

A workshop broadcast from White Oak was a shift from the fully virtual meetings held since the height of the COVID-19 pandemic and may be a step toward once again staging public events there.

US FDA Still Hasn’t Decided Who Will Be Final Arbiter On Approval Status For Covis’ Makena

With two weeks to go before hearing on whether the preterm birth prevention drug can stay on the market or be withdrawn, the lack of clarity on who will make the ultimate decision may stem from the lengthy duration of the dispute and multiple transitions within FDA’s senior leadership.

Topics

Latest News
See All
UsernamePublicRestriction

Register

MT061246

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel